Cyfuse BiomedicalCyfuse Biomedical K.K.4892東証グロース医薬品FY ending Dec 2025, non-consolidated, J-GAAP

What does Cyfuse Biomedical do with its cash?

How cash from operations was spent on investment, dividends, buybacks and more.

※ Operating cash flow is negative

Cash flow ratios

Cash conversion, investment and shareholder payments calculated from disclosed figures.

Net income-¥763.8M

Operating cash flow-¥534.8M

Nonpositive profit and free cash flow are omitted as ratio denominators. Amounts use the period's reported currency.

Operating cash flow-¥534.8M

Free cash flow-¥582.4M

Net income-¥763.8M

Operating cash flow is the cash the core business actually brought in, including changes in receivables and inventory.
Free cash flow = operating cash flow − capital expenditure: a gauge of cash available for other uses.
Large "borrowing" or "cash drawdown" flows mean the company spent more than it generated that year.

Show source documents (4)

EDINET (FSA Japan)
有価証券報告書－第16期(2025/01/01－2025/12/31)
ID S100XV4M2026-03-27Open
EDINET (FSA Japan)
有価証券報告書－第15期(2024/01/01－2024/12/31)
ID S100VGO72025-03-26Open
EDINET (FSA Japan)
有価証券報告書－第14期(2023/01/01－2023/12/31)
ID S100T55F2024-03-27Open
EDINET (FSA Japan)
有価証券報告書－第13期(2022/01/01－2022/12/31)
ID S100QGWF2023-03-28Open

Extracted from XBRL: 39 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.